Masimo (NASDAQ:MASI) Given New $194.00 Price Target at Raymond James

Masimo (NASDAQ:MASI) had its target price upped by Raymond James from $170.00 to $194.00 in a research note published on Friday morning, MarketBeat.com reports. The brokerage currently has an outperform rating on the medical equipment provider’s stock.

MASI has been the topic of several other reports. BTIG Research lifted their target price on Masimo from $166.00 to $170.00 and gave the stock a “buy” rating in a report on Monday, October 14th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $190.00 price objective (up previously from $170.00) on shares of Masimo in a research note on Friday, November 22nd. Needham & Company LLC reaffirmed a “hold” rating on shares of Masimo in a report on Wednesday, November 6th. Piper Sandler raised their target price on shares of Masimo from $180.00 to $210.00 and gave the company an “overweight” rating in a report on Wednesday, December 18th. Finally, Wells Fargo & Company upped their price target on shares of Masimo from $171.00 to $193.00 and gave the company an “overweight” rating in a research note on Wednesday, December 11th. Three investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $179.67.

Masimo Stock Down 0.0 %

Shares of MASI opened at $170.97 on Friday. Masimo has a 12-month low of $101.61 and a 12-month high of $180.97. The company has a current ratio of 2.01, a quick ratio of 1.11 and a debt-to-equity ratio of 0.50. The company has a market capitalization of $9.15 billion, a PE ratio of 117.91 and a beta of 1.01. The business’s 50 day moving average is $162.44 and its 200 day moving average is $135.91.

Masimo (NASDAQ:MASI) last released its quarterly earnings data on Tuesday, November 5th. The medical equipment provider reported $0.98 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.84 by $0.14. Masimo had a net margin of 3.85% and a return on equity of 14.98%. The firm had revenue of $504.60 million for the quarter, compared to analysts’ expectations of $502.87 million. During the same quarter last year, the business posted $0.63 earnings per share. The company’s revenue for the quarter was up 5.4% compared to the same quarter last year. Research analysts expect that Masimo will post 4.03 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Masimo

Hedge funds and other institutional investors have recently made changes to their positions in the company. NBC Securities Inc. lifted its stake in shares of Masimo by 47.1% during the 3rd quarter. NBC Securities Inc. now owns 228 shares of the medical equipment provider’s stock worth $30,000 after acquiring an additional 73 shares during the last quarter. Northwestern Mutual Wealth Management Co. increased its stake in Masimo by 133.3% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 350 shares of the medical equipment provider’s stock worth $44,000 after purchasing an additional 200 shares during the period. HHM Wealth Advisors LLC lifted its position in shares of Masimo by 25.0% during the second quarter. HHM Wealth Advisors LLC now owns 625 shares of the medical equipment provider’s stock worth $79,000 after purchasing an additional 125 shares during the last quarter. Headlands Technologies LLC purchased a new stake in shares of Masimo during the second quarter valued at $109,000. Finally, Harvest Fund Management Co. Ltd bought a new position in shares of Masimo in the third quarter worth about $118,000. Hedge funds and other institutional investors own 85.96% of the company’s stock.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.